158 related articles for article (PubMed ID: 27416572)
1. The Italian Consensus Conferences on low density lipoprotein-cholesterol apheresis.
Vogt A
Blood Transfus; 2017 Jan; 15(1):1-3. PubMed ID: 27416572
[No Abstract] [Full Text] [Related]
2. The 1
Stefanutti C
Blood Transfus; 2017 Jan; 15(1):42-48. PubMed ID: 27416576
[TBL] [Abstract][Full Text] [Related]
3. Three different schedules of low-density lipoprotein apheresis compared with plasmapheresis in patients with homozygous familial hypercholesterolemia.
Berger GM; Firth JC; Jacobs P; Wood L; Marais AD; Horak A
Am J Med; 1990 Feb; 88(2):94-100. PubMed ID: 2105647
[TBL] [Abstract][Full Text] [Related]
4. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
5. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.
Marais AD; Naoumova RP; Firth JC; Penny C; Neuwirth CK; Thompson GR
J Lipid Res; 1997 Oct; 38(10):2071-8. PubMed ID: 9374129
[TBL] [Abstract][Full Text] [Related]
6. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
Kawano M; Kuroda Y; Terao M; Yaginuma T; Kawakami M; Kanazawa Y
Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
[TBL] [Abstract][Full Text] [Related]
7. First steps toward the establishment of a German low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management.
Schettler V; Wieland E; Armstrong VW; Kleinoeder T; Grunewald RW; Müller GA;
Ther Apher; 2002 Oct; 6(5):381-3. PubMed ID: 12423533
[TBL] [Abstract][Full Text] [Related]
8. Acute Increase in Ocular Microcirculation Blood Flow Upon Cholesterol Removal. The Eyes Are the Window of the Heart.
Sampietro T; Pino BD; Bigazzi F; Sbrana F; Ripoli A; Fontanelli E; Pianelli M; Luciani R; Lepri A; Calzetti G
Am J Med; 2023 Jan; 136(1):108-114. PubMed ID: 36152804
[TBL] [Abstract][Full Text] [Related]
9. Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia.
Rubba P; Faccenda F; Di Somma S; Gnasso A; Scarpato N; Iannuzzi A; Nappi G; Postiglione A; De Divitiis O; Mancini M
Stroke; 1993 Aug; 24(8):1154-61. PubMed ID: 8342189
[TBL] [Abstract][Full Text] [Related]
10. Italian multicenter study on low-density lipoprotein apheresis Working Group 2009 survey.
Stefanutti C; Morozzi C; Di Giacomo S;
Ther Apher Dial; 2013 Apr; 17(2):169-78. PubMed ID: 23551673
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein apheresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
[TBL] [Abstract][Full Text] [Related]
12. [Reducing low density lipoprotein-cholesterol levels by apheresis].
Reiber I; Gógl A
Orv Hetil; 1994 Mar; 135(11):563-8. PubMed ID: 8159408
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Evolocumab vs low-density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01).
Torres E; Goicoechea M; Hernández A; Rodríguez Ferrero ML; García A; Macías N; Anaya F
J Clin Apher; 2020 Jan; 35(1):9-17. PubMed ID: 31663632
[TBL] [Abstract][Full Text] [Related]
14. Effects of direct adsorption of lipoproteins apheresis on lipoproteins, low-density lipoprotein subtypes, and hemorheology in hypercholesterolemic patients with coronary artery disease.
Otto C; Geiss HC; Laubach E; Schwandt P
Ther Apher; 2002 Apr; 6(2):130-5. PubMed ID: 11982953
[TBL] [Abstract][Full Text] [Related]
15. Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol.
Opole IO; Belmont JM; Kumar A; Moriarty PM
Am J Cardiol; 2007 Nov; 100(9):1416-8. PubMed ID: 17950800
[TBL] [Abstract][Full Text] [Related]
16. The effect of plasma low density lipoprotein apheresis on the hepatic secretion of biliary lipids in humans.
Hillebrant CG; Nyberg B; Einarsson K; Eriksson M
Gut; 1997 Nov; 41(5):700-4. PubMed ID: 9414982
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein apheresis in the management of severe hypercholesterolemia and hyperlipoproteinemia(a)-The Portuguese experience.
Ferreira L; Palma I; Bacelar C; Queirós JA; Madureira A; Oliveira JC; Ramos MH; Cardoso H
Transfus Apher Sci; 2018 Oct; 57(5):676-680. PubMed ID: 30287070
[TBL] [Abstract][Full Text] [Related]
18. Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein e4.
Moriarty PM; Luyendyk JP; Gibson CA; Backes JM
Am J Cardiol; 2010 Jun; 105(11):1585-7. PubMed ID: 20494666
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.
Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T
Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053
[TBL] [Abstract][Full Text] [Related]
20. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
